---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-001431"
form_type: "8-K"
ticker: "GKOS"
cik: "0001192448"
company_name: "GLAUKOS Corp"
filed_at: "2024-02-21T23:59:59+00:00"
generated_at: "2026-06-05T21:43:44.727269+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Glaukos reports record Q4 net sales $82.4M, up 16% YoY; FY2023 sales $314.7M, up 11%

## Summary
- Record Q4 2023 net sales $82.4M, up 16% YoY; glaucoma $60.6M (+15%), corneal health $21.8M (+19%).
- Q4 GAAP net loss $36.8M ($0.75/share) vs $31.5M ($0.66) YoY; non-GAAP loss $30.6M ($0.63).
- Full-year 2023 net sales $314.7M, up 11% YoY; net loss $134.7M ($2.78/share) vs $99.2M ($2.09) in 2022.
- Ended Q4 with $301M cash, equivalents & short-term investments; reaffirmed 2024 net sales guidance $350M-$360M.

## SEC filing metadata
- accession: 0001558370-24-001431
- form_type: 8-K
- ticker: GKOS
- cik: 0001192448
- company_name: GLAUKOS Corp
- filed_at: 2024-02-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1192448/000155837024001431/0001558370-24-001431-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1192448/000155837024001431/gkos-20240221x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-001431
- JSON: https://secwatch.observer/filing/0001558370-24-001431.json
- Plain text: https://secwatch.observer/filing/0001558370-24-001431.txt

## Key facts
- Earnings Releases
  GLAUKOS Corp reported the fourth quarter and full year ended December 31, 2023 results: revenue $82.4 million, net income $36.8 million, EPS ($0.75) per diluted share. Guidance reaffirmed.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Revenue: $82.4 million
  - Net income: $36.8 million
  - EPS: ($0.75) per diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023. Key highlights include: ● Record net sales of $82.4 million in Q4 2023 increased 16% year-over-year on a reported basis and 15% year-over-year on a constant currency basis. ● Glaucoma net sales of $60.6 million in Q4 2023 increased 15%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1192448/000155837024001431/0001558370-24-001431-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.